Vaccines timeline. Interview by Philip Cohen.
作者信息
Liu M A
出版信息
BMJ. 1999 Nov 13;319(7220):1301. doi: 10.1136/bmj.319.7220.1301.
Abstract
摘要
相似文献
1
Vaccines timeline. Interview by Philip Cohen.
BMJ. 1999 Nov 13;319(7220):1301. doi: 10.1136/bmj.319.7220.1301.
2
The History of Vaccines.org publishes a book.
Vaccine. 2013 Oct 1;31(42):4697. doi: 10.1016/j.vaccine.2013.07.028. Epub 2013 Jul 24.
3
Pharmacology, vaccinomics, and the second golden age of vaccinology.
Clin Pharmacol Ther. 2007 Dec;82(6):623-6. doi: 10.1038/sj.clpt.6100379.
4
[History of vaccination].
Ther Umsch. 1983 Mar;40(3):184-6.
5
[Vaccines and vaccination: a short history of vaccination].
Rev Infirm. 1999 Oct(53):20.
6
[From Jenner and Pasteur to vaccinology].
Therapie. 2005 May-Jun;60(3):201-4. doi: 10.2515/therapie:2005024.
7
Vaccines: past, present and future.
Nat Med. 2005 Apr;11(4 Suppl):S5-11. doi: 10.1038/nm1209.
8
[Not Available].
Quellen Stud Gesch Pharm. 1997;73:1-284.
9
Vaccine developments.
Nat Med. 1998 May;4(5 Suppl):515-9. doi: 10.1038/nm0598supp-515.
10
Vaccines, coming of age after 200 years.
FEMS Microbiol Rev. 2000 Jan;24(1):9-20. doi: 10.1111/j.1574-6976.2000.tb00530.x.
本文引用的文献
1
Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial.
JAMA. 1999 Jul 14;282(2):137-44. doi: 10.1001/jama.282.2.137.
2
Stable alphavirus packaging cell lines for Sindbis virus and Semliki Forest virus-derived vectors.
Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4598-603. doi: 10.1073/pnas.96.8.4598.
3
Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons.
Vaccine. 1999 Jan;17(2):99-104. doi: 10.1016/s0264-410x(98)00185-6.
4
Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato.
Nat Med. 1998 May;4(5):607-9. doi: 10.1038/nm0598-607.
5
The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children.
N Engl J Med. 1998 May 14;338(20):1405-12. doi: 10.1056/NEJM199805143382002.
6
Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity.
J Exp Med. 1998 Apr 6;187(7):1123-32. doi: 10.1084/jem.187.7.1123.
7
Recent advances in vaccine adjuvants for systemic and mucosal administration.
J Pharm Pharmacol. 1998 Jan;50(1):1-10. doi: 10.1111/j.2042-7158.1998.tb03298.x.
8
Skin immunization made possible by cholera toxin.
Nature. 1998 Feb 26;391(6670):851. doi: 10.1038/36014.
9
Safety and immunogenicity in humans of an attenuated Salmonella typhi vaccine vector strain expressing plasmid-encoded hepatitis B antigens stabilized by the Asd-balanced lethal vector system.
Infect Immun. 1997 Aug;65(8):3381-5. doi: 10.1128/iai.65.8.3381-3385.1997.
10
Attenuated bacteria as a DNA delivery vehicle for DNA-mediated immunization.
Vaccine. 1997 Jun;15(8):804-7. doi: 10.1016/s0264-410x(96)00252-6.
Zotero 插件